Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Mult Scler
; 23(6): 874-876, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-28290755
ABSTRACT
Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Citomegalovirus
/
Anticorpos Monoclonais Humanizados
/
Fatores Imunológicos
/
Esclerose Múltipla
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article